Developer docs
API playgroundTry for free, no card

Search company profiles

Roche Venture Fund

Full company profile

uuid000ex7b

Namestring
Roche Venture Fund
Legal namestring
F. Hoffmann-La Roche Ltd
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Roche Venture Fund is the corporate venture capital arm of F. Hoffmann-La Roche Ltd, a global pharmaceutical and diagnostics company headquartered in Basel, Switzerland. Established in 2002, the fund manages a CHF 750 million (approximately $940 million) evergreen capital base and invests in early to mid-stage life science companies across three core verticals: pharmaceuticals, diagnostics, and digital health. The fund's stated mission is to develop commercially successful innovative life science companies through financial investment, active portfolio involvement, and provision of strategic guidance beyond capital deployment.

The fund operates from two locations, Basel (Roche headquarters) and South San Francisco (a major US biotech hub), enabling transatlantic deal sourcing and portfolio company support. Its current portfolio comprises more than 30 companies, with the fund employing an evergreen structure that eliminates traditional fixed-fund-life constraints and allows sustained, long-term capital availability for life science development timelines. The fund focuses on generating financial returns while offering portfolio companies access to Roche's broader resources, industry expertise, and strategic partnership opportunities.

Anja Harmeier was appointed head of Roche Venture Fund in January 2025, succeeding Carole Nuechterlein who retired. Harmeier brings prior Roche Venture Fund tenure (2016-2020) and operating experience as CEO of biotech company Rewind Therapeutics. The fund does not disclose revenue, AUM-based management fees, or realized returns as a standalone entity; financial performance is reported at the parent company level. Recent activity includes co-leading a $50 million Series B financing round for COUR Pharma in June 2026, with syndication across multiple CVC partners including Lumira Ventures, Pfizer Ventures, Sanofi, and specialized funds such as T1D Fund.

Short descriptiontext

Roche Venture Fund is the corporate venture capital arm of F. Hoffmann-La Roche Ltd, managing a CHF 750M evergreen fund that invests in early to mid-stage life science companies across pharmaceuticals, diagnostics, and digital health, with operations in Basel and South San Francisco.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
corporate venture capital, life science investments, pharma venture funding, diagnostics venture investing, digital health capital
Industry1 code
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Corporate Venture Capital
Social media profiles5 records
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Roche Venture Fund is the corporate venture capital arm of F. Hoffmann-La Roche Ltd, operating a CHF 750 million evergreen fund that invests in life science companies across pharmaceuticals, diagnostics, and digital health. The fund deploys equity capital into early- to mid-stage startups while providing strategic guidance, industry expertise, and active portfolio involvement aimed at generating financial returns and fostering innovation.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Roche Venture Fund operates as a single unified investment vehicle — a CHF 750 million evergreen fund that deploys capital into life science startups in pharmaceuticals, diagnostics, and digital health. The fund provides not only capital but also strategic expertise and long-term vision to portfolio companies, aiming to develop commercially successful innovative life science companies.

Product and service1 record
1Roche Venture Fund
CategoryCorporate Venture Capital
Description

CHF 750 million evergreen corporate venture capital fund that invests in life science companies across pharmaceuticals, diagnostics, and digital health, with focus on financial returns and active portfolio involvement.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment132 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Roche Venture Fund

Corporate Venture Capitalventurefund.roche.com

Roche Venture Fund is the corporate venture capital arm of F. Hoffmann-La Roche Ltd, managing a CHF 750M evergreen fund that invests in early to mid-stage life science companies across pharmaceuticals, diagnostics, and digital health, with operations in Basel and South San Francisco.

What Roche Venture Fund does

Roche Venture Fund is the corporate venture capital arm of F. Hoffmann-La Roche Ltd, a global pharmaceutical and diagnostics company headquartered in Basel, Switzerland. Established in 2002, the fund manages a CHF 750 million (approximately $940 million) evergreen capital base and invests in early to mid-stage life science companies across three core verticals: pharmaceuticals, diagnostics, and digital health. The fund's stated mission is to develop commercially successful innovative life science companies through financial investment, active portfolio involvement, and provision of strategic guidance beyond capital deployment.

The fund operates from two locations, Basel (Roche headquarters) and South San Francisco (a major US biotech hub), enabling transatlantic deal sourcing and portfolio company support. Its current portfolio comprises more than 30 companies, with the fund employing an evergreen structure that eliminates traditional fixed-fund-life constraints and allows sustained, long-term capital availability for life science development timelines. The fund focuses on generating financial returns while offering portfolio companies access to Roche's broader resources, industry expertise, and strategic partnership opportunities.

Anja Harmeier was appointed head of Roche Venture Fund in January 2025, succeeding Carole Nuechterlein who retired. Harmeier brings prior Roche Venture Fund tenure (2016-2020) and operating experience as CEO of biotech company Rewind Therapeutics. The fund does not disclose revenue, AUM-based management fees, or realized returns as a standalone entity; financial performance is reported at the parent company level. Recent activity includes co-leading a $50 million Series B financing round for COUR Pharma in June 2026, with syndication across multiple CVC partners including Lumira Ventures, Pfizer Ventures, Sanofi, and specialized funds such as T1D Fund.

Roche Venture Fund firmographics

Firmographics
Name
Roche Venture Fund
Legal name
F. Hoffmann-La Roche Ltd
Website
https://venturefund.roche.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
10,001+ employees
Short description
Roche Venture Fund is the corporate venture capital arm of F. Hoffmann-La Roche Ltd, managing a CHF 750M evergreen fund that invests in early to mid-stage life science companies across pharmaceuticals, diagnostics, and digital health, with operations in Basel and South San Francisco.
Ownership category
akta.pro rank

Roche Venture Fund industry classification

Industry
Product category
Corporate Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)

Keywords

  • Corporate venture capital
  • Life science investments
  • Pharma venture funding
  • Diagnostics venture investing
  • Digital health capital

Where Roche Venture Fund is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Roche Venture Fund business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations

Distribution channels1 record

Marketing channels2 records

Roche Venture Fund product offering

Product offering

Core offering

Roche Venture Fund is the corporate venture capital arm of F. Hoffmann-La Roche Ltd, operating a CHF 750 million evergreen fund that invests in life science companies across pharmaceuticals, diagnostics, and digital health. The fund deploys equity capital into early- to mid-stage startups while providing strategic guidance, industry expertise, and active portfolio involvement aimed at generating financial returns and fostering innovation.

Product overview

Roche Venture Fund operates as a single unified investment vehicle — a CHF 750 million evergreen fund that deploys capital into life science startups in pharmaceuticals, diagnostics, and digital health. The fund provides not only capital but also strategic expertise and long-term vision to portfolio companies, aiming to develop commercially successful innovative life science companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Roche Venture Fund CHF 750 million evergreen corporate venture capital fund that invests in life science companies across pharmaceuticals, diagnostics, and digital health, with focus on financial returns and active portfolio involvement.

Companies that use Roche Venture Fund

Customer profile

Segments1 record

Ideal customer profiles1 record

Roche Venture Fund technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Roche Venture Fund partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves3 records

Expansion highlights4 records

Roche Venture Fund competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key highlights5 records

Customer concentration

Roche Venture Fund social profiles

Digital presence

Roche Venture Fund financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Roche Venture Fund leadership team

Management profile

Number of profiles

Profiles1 record

Roche Venture Fund funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Roche Venture Fund M&A and investment

M&A and investment

M&A

Investments132 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Venture Fund

What does Roche Venture Fund do?

Roche Venture Fund is the corporate venture capital arm of F. Hoffmann-La Roche Ltd, operating a CHF 750 million evergreen fund that invests in life science companies across pharmaceuticals, diagnostics, and digital health. The fund deploys equity capital into early- to mid-stage startups while providing strategic guidance, industry expertise, and active portfolio involvement aimed at generating financial returns and fostering innovation.

Is Roche Venture Fund a public or private company?

Roche Venture Fund is a private company. It is classified as corporate owned and is currently operating.

When was Roche Venture Fund founded?

Roche Venture Fund was founded in 2002. It employs 10,001+ people.

Where is Roche Venture Fund based?

Roche Venture Fund is headquartered in Basel, Switzerland, in the Europe region.

Does Roche Venture Fund have an API?

No public API is recorded for Roche Venture Fund.

What industry is Roche Venture Fund in?

Roche Venture Fund's product category is Corporate Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartupmagBiotech firm Mironid raises £34.1m to take ADPKD candidate into clinicMironid, a Glasgow-based biotech, raised £34.1m in a Series B round to advance its lead small-molecule programme for Autosomal Dominant Polycystic Kidney Disease (ADPKD) into clinical development. The funding will support clinical trials of its LoAc candidates, which target cAMP signalling to slow cyst growth. The company aims to de-risk the programme for later-stage partners.European BiotechnologyMironid lands $46M Series B to take kidney drug into clinicMironid raised $46 million in a Series B to advance MR-L45, a small-molecule for autosomal dominant polycystic kidney disease, into clinical development. The company will need to show its approach improves on tolvaptan, the only approved drug. The drug is in a Phase 1 trial recruiting 72 healthy adults in the Netherlands.The Pharma LetterScottish kidney disease biotech Mironid raises $46 million to advance rare disease pipelineMironid, a Glasgow-based biopharmaceutical company developing small molecule treatments for autosomal dominant polycystic kidney disease, raised $46 million in a Series B financing round. The round was led by the Scottish National Investment Bank, with Roche Venture Fund and others participating.Global VenturingFaust joins pharma company Roche’s startup investment armBryan Faust joined Roche Venture Fund as investment director, previously an investing partner at Andreessen Horowitz. The fund is a CHF 750M ($920m) evergreen fund targeting early-stage therapeutics, diagnostics, and health tech companies.DIGITGlasgow Biotech Mironid Secures £34m Series B FundingGlasgow-based biopharmaceutical company Mironid raised £34m in a Series B round, including an £8.4m equity investment from SNIB. The capital will support clinical development of its small molecule therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company aims to progress its lead candidate LoAc®.BioSpaceMironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney diseaseMironid raised $46 million in a Series B round led by Scottish National Investment Bank, with existing investors Roche Venture Fund, Epidarex Capital, Sofinnova Partners, and BioGeneration Ventures. The funding will advance clinical development of its first-in-class LoAc small molecules for Autosomal Dominant Polycystic Kidney Disease (ADPKD).The Pharma LetterCOUR Pharma raises $50 million for type 1 diabetes pushUS biotech COUR Pharma has closed a $50 million Series B financing round to advance CNP-103, its experimental type 1 diabetes therapy designed to address the autoimmune cause of the disease rather than simply managing blood glucose. The round was led by Lumira Ventures and Roche Venture Fund, with new backing from Sanofi and participation from existing investors Alpha Wave Ventures, Pfizer Ventures, Angelini Ventures, and T1D Fund. The funding will support continued development of the therapy targeting the underlying autoimmune mechanism of type 1 diabetes.GlobeNewswireCOUR Pharma Announces Closing of $50 Million Series BCOUR Pharma, a clinical-stage biotechnology company, has closed a $50 million Series B funding round led by Lumira Ventures and Roche Venture Fund, with participation from Sanofi and existing investors including Alpha Wave Ventures, Pfizer Ventures, Angelini Ventures, and T1D Fund. The proceeds will support the Phase 2 trial of CNP-103, an investigational antigen-specific immune tolerance therapy for type 1 diabetes that aims to prevent islet cell destruction by reprogramming inflammatory autoimmune responses. The company is also seeking partners for clinical development of CNP-104 in primary biliary cholangitis and CNP-106 in myasthenia gravis.BioSpaceCOUR Pharma Announces Closing of $50 Million Series BCOUR Pharma closed a $50 million Series B round led by Lumira Ventures and Roche Venture Fund, with Sanofi joining. The funds will advance CNP-103, an antigen-specific immune tolerance therapy for type 1 diabetes, in a Phase 2 trial. The company is also seeking partners for CNP-104 and CNP-106 in other autoimmune diseases.Global VenturingHarmeier heads pharma company Roche’s startup investment arm -Anja Harmeier has been appointed head of Roche Venture Fund, the corporate venture capital arm of pharmaceutical company Roche, succeeding Carole Nuechterlein who retired. Harmeier previously worked at Roche Venture Fund from 2016 to 2020 and most recently served as CEO of biotech company Rewind Therapeutics. Roche Venture Fund is a CHF 750 million (approximately $940 million) evergreen fund that invests in pharmaceutical, diagnostic, and digital health startups.